Generation and characterization of six single VP4 gene substitution reassortant rotavirus vaccine candidates: Each bears a single human rotavirus VP4 gene encoding P serotype 1A[8] or 1B[4] and the remaining 10 genes of rhesus monkey rotavirus MMU18006 or bovine rotavirus UK

Vaccine

Volumn 20, Issue 29-30, 2002, Pages 3576-3584

  Hoshino, Yasutaka ^a   Jones, Ronald W ^a   Chanock, Robert M ^a   Kapikian, Albert Z ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Rotavirus vaccine; Rotavirus VP4 and VP7; Single VP4 gene substitution rotavirus reassortants

Indexed keywords

CAPSID PROTEIN; SIMIAN ROTAVIRUS VACCINE;

ANIMAL CELL; ANTIGENICITY; ARTICLE; CATTLE; CERCOPITHECIDAE; CONTROLLED STUDY; DRUG FORMULATION; GENETIC CODE; GENETIC REASSORTMENT; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; ROTAVIRUS; SEROTYPE; VIRUS CHARACTERIZATION; VIRUS GENE; VIRUS STRAIN;

ANIMALS; ANTIGENS, VIRAL; CAPSID PROTEINS; CATTLE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; GUINEA PIGS; IMMUNIZATION; MACACA MULATTA; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS VACCINES; SEROTYPING;

EID: 0037019868     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00313-4     Document Type: Article

References (79)

1. Bern C, Glass RI. Impact of diarrheal diseases worldwide. In: Kapikian AZ, editor. Viral Infections of Gastrointestinal Tract. New York: Marcel Dekker, 1994. p. 1-26.
2. Bresee J.S., Glass R.I., Ivanoff B., Gentsch J.R. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine. 17:1999;2207-2222.
3. Kapikian AZ, Hoshino Y, Chanock RM. Rotaviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields Virology. 4th Ed. Philadelphia: Lippincott Williams & Wilkins, 2001. p. 1787-833.
4. Glass R.I., Gentsch J., Smith J.C. Rotavirus vaccines: success by reassortment? Science. 265:1994;1389-1391.
5. Advisory Committee on Immunization Practices. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. MMWR Morb. Mortal. Weekly Rep., vol. 48. 1999. p. 1-23.
6. MMWR. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb. Mortal. Weekly Rep., vol. 48. 1999. p. 577-81.
7. MMWR. Withdrawal of rotavirus vaccine recommendation. MMWR Morb. Mortal. Weekly Rep., vol. 48. 1999. p. 1007.
8. Kapikian A.Z. A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Founda. Symp. 238:2001;153-179.
9. Murphy T.V., Gargiullo P.M., Massoudi M.S.et al. Intussusception among infants given an oral rotavirus vaccine. N. Eng. J. Med. 344:2001;564-572.
10. Kramarz P., France E.K., Destefano F.et al. Population-based study of rotavirus vaccination and intussusception. Pediatr. Infect. Dis. 20:2001;410-416.
11. Simonsen L., Morens D., Elixhauser A.et al. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet. 358:2001;1224-1229.
12. Hoshino Y., Kapikian A.Z. Rotavirus serotypes: classification and importance in rotavirus epidemiology, immunity and vaccine development. J. Health Popul. Nutr. 18:2000;5-14.
13. Greenberg H.B., Valdesuso J., van Wyke K.et al. Production and preliminary characterization of monoclonal antibodies directed at two surface proteins of rhesus rotavirus. J. Virol. 47:1983;267-275.
14. Hoshino Y., Sereno M.M., Midthun K., Flores J., Kapikian A.Z., Chanock R.M. Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity. Proc. Natl. Acad. Sci. U.S.A. 82:1985;8701-8704.
15. Offit P.A., Blavat G. Identification of two rotavirus genes determining neutralization specificities. J. Virol. 57:1986;376-378.
16. Offit P.A. Immunologic determinants of protection against rotavirus disease. Curr. Topics Microbiol. Immunol. 185:1994;229-254.
17. Coste A., Sirard J.-C., Johansen K., Cohen J., Kraehenbuhl J.-P. Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea. J. Virol. 74:2000;8966-8971.
18. * subunit of VP4 capsid protein. Viral Immunol. 13:2000;187-200.
19. Hoshino Y., Saif L.J., Sereno M.M., Chanock R.M., Kapikian A.Z. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J. Virol. 62:1988;744-748.
20. Offit P.A., Clark H.F., Blavat G., Greenberg H.B. Reassortant rotaviruses containing structural proteins VP3 and VP7 from different parents induce antibodies protective against each parental serotype. J. Virol. 60:1986;491-496.
21. Offit P.A., Shaw R.D., Greenberg H.B. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins VP3 and VP7. J. Virol. 58:1986;700-703.
22. Matsui S.M., Mackow E.R., Greenberg H.B. Molecular determinant of rotavirus neutralization and protection. Adv. Virus Res. 36:1989;181-214.
23. Gentsch J.R., Woods P.A., Ramachandran M.et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J. Infect. Dis. 174(Suppl):1996;S30-S36.
24. Koshimura Y., Nakagomi T., Nakagomi O. The relative frequencies of G serotypes of rotaviruses recovered from hospitalized children with diarrhea: a 10-year survey (1987-1996) in Japan with a review of globally collected data. Microbiol. Immunol. 44:2000;499-510.
25. Kapikian AZ. Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea in infants and young children: an introduction. In: Kapikian AZ, editor. Viral Infections of the Gastrointestinal Tract. New York: Marcel Dekker, 1994. p. 409-17.
26. Midthun K., Greenberg H.B., Hoshino Y., Kapikian A.Z., Wyatt R.G., Chanock R.M. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J. Virol. 53:1985;949-954.
27. Midthun K., Hoshino Y., Kapikian A.Z., Chanock R.M. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J. Clin. Microbiol. 24:1986;822-826.
28. Clements-Mann M.L., Makhene M.K., Mrukowicz J.et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine. 17:1999;2715-2725.
29. Clements-Mann M.L., Dudas R., Hoshino Y.et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine. 14:2001;4676-4684.
30. Clark H.F., Offit P.A., Ellis R.W.et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J. Infect. Dis. 174(Suppl):1996;S73-S80.
31. Hoshino Y., Kapikian A.Z., Chanock R.M. Selection of cold-adapted mutants of human rotaviruses that exhibit various degrees of growth restriction in vitro. J. Virol. 68:1994;7598-7602.
32. Hoshino Y., Jones R.W., Chanock R.M., Kapikian A.Z. Construction of four double gene substitution human × bovine rotavirus reassortant vaccine candidates: each bears two outer capsid human rotavirus genes, one encoding P serotype 1A and the other encoding G seotype 1, 2, 3 or 4 specificity. J. Med. Virol. 51:1997;319-325.
33. Wyatt RG, Kapikian AZ, Hoshino Y, et al. Development of rotavirus vaccines. In: Proceedings of the International Symposium on Control and Eradication of Infectious Diseases. Washington (DC): PAHO Copublication Series No. 1, 1985. p. 17-28.
34. Wyatt R.G., James H.D. Jr., Pittman A.L.et al. Direct isolation in cell culture of human rotaviruses and their characterization into four serotypes. J. Clin. Microbiol. 18:1983;310-317.
35. Wyatt R.G., Greenberg H.B., James H.D. Jr.et al. Definition of human rotavirus serotypes by plaque reduction assay. Infect. Immun. 37:1982;110-115.
36. Gerna G., Passarani N., Sarasini A., Battaglia M. Characterization of serotypes of human rotavirus strains by solid-phase immune electron microscopy. J. Infect. Dis. 152:1985;1143-1151.
37. Clark H.F., Hoshino Y., Bell L.M.et al. Rotavirus WI61 representing a presumptive new human serotype. J. Clin. Microbiol. 25:1987;1757-1762.
38. Urasawa S., Urasawa T., Wakasugi F.et al. Presumptive seventh serotype of human rotavirus. Arch. Virol. 113:1990;279-282.
39. Hoshino Y., Wyatt R.G., Flores J., Midthun K., Kapikian A.Z. Serotypic characterization of rotaviruses derived from asymptomatic human neonatal infections. J. Clin. Microbiol. 21:1985;425-430.
40. Urasawa S., Urasawa T., Taniguchi K. Three human rotavirus serotypes demonstrated by plaque neutralization of isolated strains. Infect. Immun. 38:1982;781-784.
41. Kitaoka S., Nakagomi T., Fukuhara N.et al. Serologic characteristics of a human rotavirus AU-1 which has a long RNA pattern and subgroup 1 specificity. J. Med. Virol. 23:1987;352-357.
42. Matsuno S., Mukoyama A., Hasegawa A., Taniguchi K., Inouye S. Characterization of a human rotavirus strain which is possibly a naturally-occurring reassortant virus. Virus Res. 10:1988;167-175.
43. Matsuno S., Hasegawa A., Mukoyama A., Inouye S. A candidate for a new serotype of human rotavirus. J. Virol. 54:1985;623-624.
44. Aboudy Y., Shif I., Zilberstein I., Gotlieb-Stematsky T. Use of polyclonal and monoclonal antibodies and analysis of viral RNA in the detection of unusual group: a human rotaviruses. J. Med. Virol. 25:1988;351-359.
45. Gerna G., Sarasini A., Parea M.et al. Isolation and characterization of two distinct human rotavirus strains with G6 specificity. J. Clin. Microbiol. 30:1992;9-16.
46. Stuker G., Oshiro L., Schmidt N.J. Antigenic comparisons of two new rotaviruses from rhesus monkey. J. Clin. Microbiol. 11:1980;202-203.
47. Woode G.N., Jones J., Bridger J. Levels of colostral antibodies against neonatal calf diarrhea virus. Vet. Rec. 97:1975;148-149.
48. Shaw R.D., Stoner-Ma D.L., Estes M.K., Greenberg H.B. Specific enzyme-linked immunoassay for rotavirus serotypes 1 and 3. J. Clin. Microbiol. 22:1985;286-291.
49. Taniguchi K., Urasawa T., Morita Y., Greenberg H.B., Urasawa S. Direct serotyping of human rotavirus in stools by an enzyme-linked immunosorbent assay using seroype 1-, 2-, 3-, or 4-specific monoclonal antibodies to VP7. J. Infect. Dis. 155:1987;1159-1166.
50. Snodgrass D.R., Fitzgerald T., Campbell I.et al. Rotavirus serotypes 6 and 10 predominate in cattle. J. Clin. Microbiol. 28:1990;504-507.
51. Green K.Y., James H.D. Jr., Kapikian A.Z. Evaluation of three panels of monoclonal antibodies for the identification of human rotavirus VP7 serotype by ELISA. Bull. WHO. 68:1990;601-610.
52. Losonsky G.A., Rennels M.B., Lim Y., Krall G., Kapikian A.Z., Levine M. Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU18006. Pediatr. Infect. Dis. J. 7:1988;388-393.
53. Green K.Y., Taniguchi K., Mackow E.R., Kapikian A.Z. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccines: implications for vaccine development. J. Infect. Dis. 16:1990;667-679.
54. Bernstein D.I., Glass R.I., Rodgers G.et al. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US rotavirus vaccine efficacy group. J. Am. Med. Assoc. 273:1995;1191-1196.
55. Rennels M.B., Glass R.I., Dennehy P.H.et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the national multicenter trials. Pediatrics. 97:1996;7-13.
56. Kapikian A.Z., Hoshino Y., Chanock R.M., Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J. Infect. Dis. 174(Suppl):1996;S65-S72.
57. Ward R.L., Knowlton D.R., Zito E.T.et al. Serologic correlates of immunity in a tetravalent rotavirus vaccine trial. J. Infect. Dis. 176:1997;570-577.
58. Perez-Schael I., Guntinas M.J., Perez M.et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N. Engl. J. Med. 337:1997;1181-1187.
59. Joensuu J., Koskenniemi E., Pang X.L., Vesikari T. Randomised palcebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 350:1997;1205-1209.
60. Snodgrass D.R., Fitzgerald T.A., Campbell I.et al. Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naïve and experienced animals. J. Clin. Microbiol. 29:1991;2668-2672.
61. Offit P.A., Hoffenberg E.J., Santos N., Gouvea V. Rotavirus-specific humoral and cellular immune response after primary symptomatic infection. J. Infect. Dis. 167:1993;1436-1440.
62. Rojas A.M., Boher Y., Guntinas M.J., Perez-Schael I. Homotypic immune response to primary infection with rotavirus serotype G1. J. Med. Virol. 47:1995;404-409.
63. Gorrell R., Bishop R. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children. J. Med. Virol. 57:1999;204-211.
64. Gorziglia M., Larralde G., Kapikian A.Z., Chanock R.M. Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4. Proc. Natl. Acad. Sci. U.S.A. 87:1990;7155-7159.
65. Hoshino Y., Kapikian A.Z. Classification of rotavirus VP4 and VP7 serotypes. Arch. Virol. 12(Suppl.):1996;99-111.
66. Gouvea V., de Castro L., Timenetsky M.C.S.T., Greenberg H.B., Santos N. Rotavirus serotype G5 associated with diarrhea in Brazilian children. J. Clin. Microbiol. 32:1994;1408-1409.
67. Gouvea V., Santos N. Rotavirus serotype G5: an emerging cause of epidemic childhood diarrhea. Vaccine. 17:1999;1291-1292.
68. Leite J.P., Alfieri A.A., Woods P.A., Glass R.I., Gentsch J.R. Rotavirus G and P types circulating in Brazil: characterization by RT-PCR, probe hybridization, and sequence analysis. Arch. Virol. 141:1996;2365-2374.
69. Timenetsky M.C.S.T., Santos N., Gouvea V. Survey of rotavirus G and P types associated with human gastroenteritis in Sãn Paulo, Brazil, from 1986 to 1992. J. Clin. Microbiol. 32:1994;2622-2624.
70. Bok K., Castagnaro N., Borsa A.et al. Surveillance for rotavirus in Argentina. J. Med. Virol. 65:2001;190-198.
71. Unicomb L.E., Podder G., Gentsch J.R.et al. Evidence of high-frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995. J. Clin. Microbiol. 37:1999;1885-1891.
72. Ramachandran M., Gentsch J.R., Parashar U.D.et al. Detection and characterization of novel rotavirus strains in the US. J. Clin. Microbiol. 36:1998;3223-3229.
73. Palombo E.A., Masendycz P.J., Bugg H.C.et al. Emergence of serotype G9 human rotaviurses in Australia. J. Clin. Microbiol. 38:2000;1305-1306.
74. O'Halloran F., Lynch M., Cryan B., O'Shea H., Fanning S. Molecular characterization of rotavirus in Ireland: detection of novel strains circulating in the population. J. Clin. Microbiol. 38:2000;3370-3374.
75. Santos N., Volotao E.M., Soares C.C.et al. Rotavirus strains bearing genotype G9 or P[9] recovered from Brazilian children with diarrhea from 1997 to 1999. J. Clin. Microbiol. 39:2001;1157-1160.
76. Araujo I.T., Ferreira M.S., Fialho A.M.et al. Rotavirus genotypes P[4]G9, P[6]G9, and P[8]G9 in hospitalized children with acute gastroenteritis in Rio de Janeiro, Brazil. J. Clin. Microbiol. 39:2001;1999-2001.
77. Hoshino Y., Saif L.J., Kang S.Y.et al. Identification of group A rotavirus genes associated with virulence of a porcine rotavirus and host range restriction of a human rotavirus in the gnotobiotic piglet model. Virology. 209:1995;274-280.
78. Eichelberger M.C., Sperber E., Wagner M.et al. Clinical evaluation of a single oral dose of human-bovine (UK) reassortant rotavirus vaccines Wa × UK (P1A[8], G6) and Wa × (DS-1 × UK) (P1A[8], G2). J. Med. Virol. 66:2002;407-416.
79. Jones RW, Ross J, Hoshino Y. Identification of Parental Origin of Cognate dsRNA Genome Segment(s) of Rotavirus Reassortants by Constant Denaturant Gel Electrophoresis, in press.